Journal of Pharmaceutical Investigation

  • 제35권4호
  • /
  • Pages.273-278
  • /
  • 2005
  • /
  • 2093-5552(pISSN)
  • /
  • 2093-6214(eISSN)
한국약제학회 (The Korean Society of Pharmaceutical Sciences and Technology)
권호 표지
DOI QR코드

DOI QR Code

생체내 예측 및 흰쥐를 이용한 니코틴 패취의 약물동력학적 평가

In Vivo Prediction and Biopharmaceutical Evaluation of Nicotine Transdermal Patch

  • 발행 : 2005.08.20
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Nicotine transdermal therapeutic systems $(TTS_S)$ have been regarded as an effective mean to aid smoking cessation. However, most of nicotine $TTS_S$ in the market have some problems such as unpleasant side effects and skin irritation due to the excess amount of the drug permeated and the properties of the additives employed. In order to solve these problems, new nicotine $TTS_S$ were formulated using biocompatible additives. The optimized formula of the drug layer consisted of nicotine, propylene glycol and poloxamer 188 at the ratio of 1.2: 17.0: 2.0. The drug layer had the sickness of $1,250\;{\mu}m$, the pH of 8.12. The skin permeation rate of nicotine from optimized nicotine patch (NP) was $21.5\;{\mu}g/cm^2/h$. Transdermal administration of nicotine patch has been carried out for the determination of pharmacokinetic parameters in rats. Steady-state plasma concentration of nicotine following transdermal application of NP (area of patch = $15\;cm^2$) on the dorsal skin of rats was 143.2 ng/ml and AUC for 24 hrs was 3,022 ng h/ml. In case of $EXODUS^{\circledR}$ and Nicotinell $TTS^{\circledR}$, the steady-state plasma concentration of nicotine and ACU for 24 hrs were 428.9 ng/ml, $9,121\;ng{\cdot}hr/ml$ and 155.3 ng/ml, $3,152\;ng{\cdot}h/ml$, respectively. NP showed the experimental plasma nicotine concentration profile was very similar to the simulated one and had an appropriate skin permeation rate and a steady-state concentration of nicotine, which can show therapeutic blood levels of the drug for 24 hrs without severe side effects.

키워드

참고문헌

  1. C.B. Thomas, Familial and epidemiologic aspects of coronary disease and hypertension, J. Chron. Dis., 7, 198 (1958) https://doi.org/10.1016/0021-9681(58)90026-2
  2. M.M. Weir, J.F. Dunn and P.E. Buell, Smoking and oral cancer: epidemiological data, educational responses, Am. J. Public Health., 59(6), 959-966 (1969) https://doi.org/10.2105/AJPH.59.6.959
  3. E.N. Valentine, Squamous metaplasia of the brochus, Cancer, 10, 272-279 (1957) https://doi.org/10.1002/1097-0142(195703/04)10:2<272::AID-CNCR2820100209>3.0.CO;2-L
  4. S.C. Mulligan, J.G. Masterson, J.G. Devane and J.G. Kelly, Clinical and pharmacokinetic properties of a transdermal nicotine patch, Clin Pharmacol. Ther., 47(3), 331-337 (1990) https://doi.org/10.1038/clpt.1990.36
  5. S.K. Gupta, R.A. Okerholm, P. Coen, R.D. Prather and J. Gorsline, Single- and multiple-dose pharmacokinetics of nicoderm (Nicotine transdermal system), J. Clin Pharmacol., 33, 169-174 (1993) https://doi.org/10.1002/j.1552-4604.1993.tb03939.x
  6. K.K.H. Chan, H.D. Ross, B. Berner, A.J. Piraino and V.A. John, Pharmacokinetics of a single transdermal dose of nicotine in healthy smokers, J. Controlled Release, 14, 145-151 (1990) https://doi.org/10.1016/0168-3659(90)90151-I
  7. N.L. Benowitz, K. Chan, C.P. Denaro and P.I. Jacob III, Stable isotope method for studying trans dermal drug absorption : the nicotine patch, Clin. Pharmacol. Ther., 50(3),286-293 (1991) https://doi.org/10.1038/clpt.1991.138
  8. N.L, Benowitz, P.I. Jacob III, P. Olsson and C.J. Johansson, Intravenous nicotine retards transdermal absorption of nicotine : evidence of blood flow-limited percutaneous absorption, Clin. Pharmacol. Ther., 52(3) 223-230 (1992) https://doi.org/10.1038/clpt.1992.134
  9. G.M. Kochak, J.X. Sun, R.L. Choi and A.J. Piraino, Pharmacokinetic disposition of multiple-dose transdermal nicotine in healthy adult smokers, Pharm. Res., 9(11), 1451-1455 (1992) https://doi.org/10.1023/A:1015862930096
  10. S. Caspary, B. Keller-Stanislawski, T. Huber and P.-G. Merz, Phannacokinetics of nicotine after application of a 30 $cm^2$ nicotine patch under steady-state conditions, Int. J. Clin. Pharmacol. Ther. Toxicol., 29(3),92-95 (1991)
  11. S. Lin and Y.W. Chien, Transdermal nicotine delivery systems: multi-institutional cooperative bioequivalence studies, Drug Dev. Ind. Pharm., 19(20), 2765-2793 (1993) https://doi.org/10.3109/03639049309050177
  12. D.R. Plowchalk. M.E. Andersen and J.D. Debetbizy, A physiologically based pharmacokinetics model for niotine disposition in the Sprague-Dawley rat, Toxico. Appl. Pharmacol., 116, 177-188 (1992) https://doi.org/10.1016/0041-008X(92)90297-6
  13. G.A. Kyerematen, L.H. Taylor, J.D. Debethizy and E.S. Vesell, Phannacokinetics of nicotine and 12 metabolites in the rat, Drug Metab. Dispos. Biol. Chem., 16(1), 125-129 (1988)
  14. K.S. Rotenberg and J. Adir, Pharmacokinetics of nicotine in rats after multiple cigarette smoke exposure, Toxico. Appl. Pharmacol., 69, 1-11 (1983) https://doi.org/10.1016/0041-008X(83)90113-8
  15. K.S. Rotenberg, R.P. Miller and J. Adir, Pharmacokinetics of nicotine in rats after single-cigarette smoke inhalation, J. Pharm. Sci., 69(9), 1087-1090 (1980) https://doi.org/10.1002/jps.2600690927
  16. S.C. Shin and J.S. Choi, Enhanced bioavailability of triprolidine from the transdermal TPX matrix system in rabbits, Int. J. Pharm., 234(1-2), 67-73 (2002) https://doi.org/10.1016/S0378-5173(01)00960-7
  17. S.C. Shin and J.S. Choi, Enhanced bioavailability of atenolol by transdermal administration of the ethylene-vinyl acetate matrix in rabbits, Eur. J. Pharm. Biopharm., 56(3), 439-43 (2003) https://doi.org/10.1016/S0939-6411(03)00133-4
  18. B. W. Barry, Dermatological formulations, Marcel Dekker, Inc., New York (1983)
  19. V.P. Shah and H.I. Maibach, Topical drug bioavailability, bioequivalence, and penetration, Plenum, 29 (1993)
  20. C.-C. Chiang, Transdermal nicotine absorption dosage unit and process, WO 93/00057 (1993)